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DOI 10.1016/j.immuni.2008.09.011We appreciate the opportunity to contribute
to the interesting discussion initiated by the
letter to the editor by Lazarski et al. In their
letter, the authors raise the possibility that re-
duced CD25 expression on T regulatory
(Treg) cells is a common feature of inflamma-
tion, not a specific autoimmune defect (Laz-
arski et al., 2008). This hypothesis has critical
implications for the basis of CD25 regulation
and potential therapeutic use of IL-2 ago-
nists in the clinical setting.
CD25 is more than a commonly used cell-
surface marker on Treg cells. As a compo-
nent of the high-affinity IL-2 receptor, CD25
endows the Treg cells with the ability to
sense low amounts of IL-2 in the steady state
to promote their survival and provide an es-
sential functional receptor critical for Treg
cell homeostasis (Fontenot et al., 2005). In
a recently published Immunity paper, we
highlighted the key functional role of CD25
expression on Treg cells in the pathogenesis
of spontaneous autoimmunity in nonobese
diabetic (NOD) mice. We demonstrated that
Treg cells in the inflamed islets of prediabetic
NOD mice showed reduced CD25 expres-
sion when compared with their lymph node
counterparts (Tang et al., 2008). The low
CD25 expression was associated with re-
duced intracellular antiapoptotic protein
(Bcl-2) expression in Treg cells and loss of
Treg cell:effector T cell balance in the islets.
Because both CD25 and Bcl-2 expression is
regulated by IL-2, and intraislet T cells pro-
duced less IL-2 than T cells in the lymph no-
des (LNs), we suggested that the defect in
intraislet Treg cell survival may be second-
ary to an IL-2 defect, a genetically encoded
trait in the NOD mice (Yamanouchi et al.,
2007). In contrast, Lazarski et al. (2008) sug-
gest that the CD25 defect may have little to
do with autoimmunity but rather be a general
consequence of inflammation. In support of
this idea, we reported that the defect in
CD25 and Bcl-2 expression in Treg cells iso-
lated from NOD mice was clearly most pro-
nounced in inflamed tissues such as islets512 Immunity 29, October 17, 2008 ª2008 Eland lachrymal and salivary glands (Tang et
al., 2008).
However, a number of studies suggest
that the loss of CD25 on Treg cells is more
complicated. First, we observed a similar re-
duction in CD25 and Bcl-2 expression in in-
traislet Treg cells in diabetes-resistant
NOD.B6.Idd3 mice when compared with in-
traislet Treg cells from standard NOD stocks
(Figure S1A available online). The idd3 loci
contain the Il2 gene; thus, the presence of
the B6 idd3 allele in the NOD.B6.idd3 mice
replaces the diabetes-prone NOD IL-2
gene with the diabetes-resistant B6 Il2
gene. This result suggests that loss of
CD25 expression on Treg cells from the
site of inflammationmay be a general feature
of inflammation independent of the IL-2 al-
lele and disease status. Similarly, the islet
antigen-specific BDC2.5 T cell receptor
(TCR) transgenicmouse develops large non-
pathogenic intraislet infiltrates. In this set-
ting, fully half of the intraislet Treg cells ex-
press normal amounts of Bcl-2 when
compared to that found in the LN Treg cells
(Figure S1B). Second, we have observed in
another diabetes model that intraislet Treg
cells can express high amount of CD25, sim-
ilar to Treg cells in the periphery, despite rag-
ing inflammation and progressive develop-
ment of diabetes (Figure S1C). In this
model, mice expressing a model-antigen
chicken ovalbumin (OVA) on b-cells were
crossed to OVA-reactive TCR transgenic
DO11.10 mice. Treg cell isolated from in-
flamed islets showed no evidence of com-
promised Treg cell function or survival, and
onset of diabetes was associated with IL-
21 expression and effector T cell resistance
to regulation (Clough et al., 2008). Thus, not
all Treg cells at sites of inflammation lose
CD25 expression. Lastly, the fact that we
have observed that Treg cells isolated from
various healthy tissues in steady state ex-
pressed variable amounts of CD25, with
liver-resident Treg cells expressing the low-
est amount of CD25, demonstrates that thesevier Inc.CD25 expression on Treg cells may be de-
pendent on the tissue in which they reside
(Figure S1D).
Taken together, we believe that regulation
of CD25 expression on Treg cells at site of in-
flammation is probably not controlled by
a single parameter. Rather, the totality of
the results suggests that both autoimmune
and nonautoimmune factors contribute to
this localized phenomenon including re-
duced expression of IL-2 by effector T cells,
inhibition of IL-2 production by inflammatory
cytokines, activation of proteases that
cleave CD25 from the cell surface, and com-
petition for IL-2 by activated effector T cells.
Thus, we propose that general inflamma-
tion, composition of the inflammatory milieu,
and tissue location, as well autoimmune ge-
netic background, may all contribute to this
Treg cell defect. Further studies will help to
determine whether similar observations in
humans will lead to therapeutic approaches
that can ‘‘repair’’ the Treg cell defects and
yet maintain immune competence.
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